Rezolute, Inc.

NasdaqCM RZLT

Rezolute, Inc. Price to Book Ratio (P/B) on January 14, 2025: 2.76

Rezolute, Inc. Price to Book Ratio (P/B) is 2.76 on January 14, 2025, a 608.83% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Rezolute, Inc. 52-week high Price to Book Ratio (P/B) is 3.48 on November 11, 2024, which is 26.27% above the current Price to Book Ratio (P/B).
Rezolute, Inc. 52-week low Price to Book Ratio (P/B) is 0.37 on January 17, 2024, which is -86.73% below the current Price to Book Ratio (P/B).
Rezolute, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 1.78.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: RZLT

Rezolute, Inc.

CEO	Mr. Nevan Charles Elam J.D.
IPO Date	Jan. 14, 2013
Location	United States
Headquarters	201 Redwood Shores Parkway
Employees	59
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Key trends

Past 5 years